Agilent Expects 2- to 5-Percent Decline in Q3 Revenue; Closes Stratagene Buy | GenomeWeb
NEW YORK (GenomeWeb News) — Agilent Technologies today said it expects third-quarter revenue to decline between 2 percent and 4.8 percent year over year, or to between $1.38 billion and $1.42 billion from $1.45 billion last year.
The company also said it has closed its acquisition of Stratagene for $10.94 a share, or $246 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.